Altimmune Inc (ALT) Price Chart

Public company logo of Altimmune Inc (ALT)

This daily price action, visualized for analytical convenience, helps assess the impact of strict FDA oversight and patent protection on Altimmune, Inc. (ALT) shares. The company is currently focused on completing Phase 2 trials of pemvidutide while seeking a partner. Business revenues will be based on GLP-1 drug sales to obese patients, with the current metric standing at 1.94.

Altimmune, Inc. - ALT Price (period 07/04/2022 - 11/11/2026)

Financial and market metric breakdowns for Altimmune Inc (ALT)

- stock quotes and analyst forecast:
Stock Price Altimmune, Inc.|ALT - Analyst Consensus Forecast
- market capitalization details:
Market Value Altimmune Inc|ALT - Total Company Value
- balance sheet equity data:
Accounting Value per Share Altimmune|ALT - Total Net Assets|Market Value to Book Value Ratio altimmune.com|ALT - Total Asset Value of Company
- debt obligations and liquidity statistics:
Total Debt to Capital Altimmune, Inc.|ALT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Altimmune Corp|ALT - Company Aggregate Debts|Debt to Book Capitalization Ratio Altimmune Inc|ALT - Company Long-Term Loans and Borrowings|Company Short-Term Debt Altimmune|Quick Ratio altimmune.com
- financial results and valuation multiples details:
ALT - Net Profit|Future Profit Altimmune, Inc.|ALT - Company Value to Net Income|Future Price to Earnings Altimmune|ALT - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Altimmune Inc|ALT - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Altimmune|ALT - Earnings per share for the last four quarters|Quarterly EPS earnings growth altimmune.com|ALT - Earnings growth in current year|Earnings growth forecast for next year Altimmune, Inc.
Comprehensive company analysis:ALT Altimmune, Inc.
Brand item of Altimmune Inc

The price aggregates the market valuation of all operating expenses and expected revenues, serving as an objective measure of the business's fundamental stability through investor consensus. For Altimmune, Inc. (ALT), real-time price volatility reflects the market's sensitivity to Pemvidutide trial results and competition with industry behemoths, turning the chart into an indicator of confidence in the drug's commercial success.

Direct competitors

Stock Price ASND|Stock Price madrigalpharma.com (MDGL)|Price Chart Corcept Therapeutics Incorporated CORT|Rhythm Pharma - Price Chart|AKRO: Stock Quotes|Metsera Therapeutics - Price|MoonLake Immunotherapeutics (MLTX) - Price Chart|Quote Chart CRNX (crinetics.com)|NAMS (NewAmsterdam Pharma Company N.V.) - Stock Price|SLNO: Price Performance Chart|Stock Price FOLD|Stock Price 89bio Pharma (ETNB)|Price Chart Agios Pharmaceuticals AGIO|Price Performance Chart GPCR|MDXG - Price Chart|Rezolute Inc (RZLT) - Stock Quotes|LXRX: Stock Price|MBX Corp (MBX) - Stock Price|Stock Quotes AARD|SGMT: Price Performance Chart|Price Chart BioAge (BIOA)|Stock Quotes Biomea Fusion Inc BMEA|Stock Price QNCX (Quince Therapeutics, Inc.)|Fractyl Health, Inc (GUTS) - Market Price|VTVT: Stock Quotes|Agape ATP Corporation - Price|PLUR: Stock Price|Synlogic (SYBX) - Stock Price|LPCN (Lipocine Corp) - Stock Price|Price Chart MTNB|Price Chart Spruce Biosciences, Inc. (SPRB)|GLTO - Market Price|Price Chart Carmell CTCX|Lumos Pharma Inc - Price Chart|Organovo Holdings Inc - Stock Price|Market Chart Radius Pharmaceuticals RDUS